Search
Powered By HealthLine
Health Tools
 Children's Allergies Q&A
 Childhood Asthma Guide
 Childhood Asthma Prognosis
 Identifying Depression in Children
 Treating Childhood Depression
Featured Conditions
 Cold & Flu
 Allergy
 Asthma
 Depression
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
Drug DescriptionSide Effects & Drug InteractionsWarnings & Precautions
Clinical PharmacologyOverdosage & ContraindicationsIndications & DosagePatient Info

Procrit

[Epoetin alfa]


Overdosage & Contraindications
CONTRAINDICATIONS

PROCRIT is contraindicated in patients with: 1) Uncontrolled hypertension. 2) Known hypersensitivity to mammalian cell-derived products. 3) Known hypersensitivity to Albumin (Human).

OVERDOSAGE

Text Continues Below



The maximum amount of PROCRIT that can be safely administered in single or multiple doses has not been determined. Doses of up to 1,500 Units/ kg (T. I. W.) for three to four weeks have been administered to adults without any direct toxic effects of PROCRIT itself. Therapy with PROCRIT can result in polycythemia if the hematocrit is not carefully monitored and the dose appropriately adjusted. If the suggested target range is exceeded, PROCRIT may be temporarily withheld until the hematocrit returns to the suggested target range; PROCRIT therapy may then be resumed using a lower dose (see "DOSAGE AND ADMINISTRATION"). If polycythemia is of concern, phlebotomy may be indicated to decrease the hematocrit.









HealthScout is a part of HealthCentral
About Us   Our Blog   Contact Us   Privacy Policy   Terms of Use   Site Map  
Copyright © 2001-2013. The HealthCentralNetwork, Inc. All rights reserved.
Advertising Policy   Editorial Policy Advertise With Us   Anti-Spam Policy   PR Newswire